Evidence map›Paper›PMID 25591736›Full record

ArticleCell death and differentiation2015

LAMC2 enhances the metastatic potential of lung adenocarcinoma.

Y W Moon, G Rao, J J Kim, H-S Shim, K-S Park, S S An, B Kim, P S Steeg, S Sarfaraz, L Changwoo Lee and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death and differentiation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Enhanced antitumor efficacy of combined targeting of adenosine ACancer immunology, immunotherapy : CII · 2026
    Article
  7. LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway.International journal of chronic obstructive pulmonary disease · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Y W Moon1] Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA [2] Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
G RaoLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
J J KimDepartment of Bioengineering, Johns Hopkins University, Baltimore, MD, USA.
H-S ShimDepartment of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
K-S Park1] Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA [2] Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
S S AnDepartment of Environmental Health Sciences, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
B KimPathology Branch, National Cancer Institute, National Institutes of Health, MD, USA.
P S SteegWomen's Cancers Section, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
S SarfarazMedical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
L Changwoo LeeMedical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Donna VoellerMedical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
E Y ChoiDepartment of Environmental Health Sciences, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Ji LuoMedical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
D PalmieriWomen's Cancers Section, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
H C ChungDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
J-H KimDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Y Wang1] Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA [2] Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
G Giaccone1] Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA [2] Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
National Cancer Institute · USJohns Hopkins University · USNational Institutes of Health · USGeorgetown University · USYonsei University · KRGeorgetown University Medical Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
Theranostic Imaging of Metastatic Prostate CancerP50CA103175 · NCI · JOHNS HOPKINS UNIVERSITY · PI BARKER, PETER B · 2003 to 2015
$17.9M
Molecular Analysis of Breast Cancer Metastasis to the BrainZIABC010538 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STEEG, PATRICIA SCHRIVER · 2009 to 2025
$17.1M
TRANS NETWORK PROJECTSU54CA143868 · NCI · JOHNS HOPKINS UNIVERSITY · PI SEARSON, PETER C · 2009 to 2013
$13.7M
Lung Cancer ProgramZ01BC010854 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GIACCONE, GIUSEPPE · 2007 to 2008
$2.6M
Nrf2 as a critical determinant of smooth muscle functionR01HL107361 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI AN, STEVEN S · 2011 to 2015
$2.0M
Raman spectroscopy probes for assisting stereotactic breast biopsy needle placemeR43CA141868 · NCI · NEWTON LABORATORIES · PI FULGHUM, STEPHEN FREDERICK · 2009 to 2009
$100k
NCI NIH HHS P30 CA051008NCI NIH HHS P30 CA51008NCI NIH HHS P50 CA103175NCI NIH HHS P50CA103175NCI NIH HHS R43 CA141868NCI NIH HHS U54CA141868NCI NIH HHS U54 CA143868NHLBI NIH HHS HL107361NHLBI NIH HHS R01 HL107361
6 · The paper itself

Abstract

Lung cancer is the number one cancer killer, and metastasis is the main cause of high mortality in lung cancer patients. However, mechanisms underlying the development of lung cancer metastasis remain unknown. Using genome-wide transcriptional analysis in an experimental metastasis model, we identified laminin γ2 (LAMC2), an epithelial basement membrane protein, to be significantly upregulated in lung adenocarcinoma metastatic cells. Elevated LAMC2 increased traction force, migration, and invasion of lung adenocarcinoma cells accompanied by the induction of epithelial-mesenchymal transition (EMT). LAMC2 knockdown decreased traction force, migration, and invasion accompanied by EMT reduction in vitro, and attenuated metastasis in mice. LAMC2 promoted migration and invasion via EMT that was integrin β1- and ZEB1-dependent. High LAMC2 was significantly correlated with the mesenchymal marker vimentin expression in lung adenocarcinomas, and with higher risk of recurrence or death in patients with lung adenocarcinoma. We suggest that LAMC2 promotes metastasis in lung adenocarcinoma via EMT and may be a potential therapeutic target.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAnimalsCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionFemaleHumansLamininLung NeoplasmsMiceLAMC2 protein, humanLamc2 protein, mouseLaminin

Identifiers

PMID25591736
PMCPMC4495359
OpenAlexW1988251250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.